Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genelabs' lupus protocol

Lupus has been a tough nut to crack in the clinic because of its unpredictable flares and propensity to strike different organs in different people. Genelabs Technologies Inc. on Sunday presented positive data from its latest Phase III trial of GL701 dehydroepiandrosterone (DHEA) to treat the disease. The company said that the trial, which was designed

Read the full 565 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers